Veracyte (VCYT)

• Market cap: $3.14B
• 1 day: -1.27%
• 5 days: -2.66%
• 1 month: -3.93%
• 3 months: 18.27%
• 6 months: 60.52%
• Year to date: 0.35%
• 1 year: 58.52%
• 5 years: 34.59%
• 10 years: 383.67%
• Sector: Healthcare
• Industry: Medical Laboratories

Fund manager confidence

Based on 2024 Q3 regulatory filings by fund managers ($100M+ AUM)

911% more call options, than puts

Call options by funds: $4.58M | Put options by funds: $453K

245% more first-time investments, than exits

New positions opened: 76 | Existing positions closed: 22

55% more capital invested

Capital invested by funds: $1.8B [Q2] → $2.79B (+$990M) [Q3]

21% more funds holding

Funds holding: 238 [Q2] → 289 (+51) [Q3]

6% less repeat investments, than reductions

Existing positions increased: 85 | Existing positions reduced: 90

1.3% less ownership

Funds ownership: 108.5% [Q2] → 107.21% (-1.3%) [Q3]

Research analyst outlook

5 Wall Street Analysts provided 1 year price targets over the past 3 months

• Low target: $28 31% downside
• Avg. target: $40 2% downside
• High target: $46 13% upside

5 analyst ratings

• positive: 3 60%
• neutral: 1 20%
• negative: 1 20%

Goldman Sachs Matthew Sykes 60% 1-year accuracy 25 / 42 met price target	9% downside $37	Neutral Downgraded	5 Dec 2024
Morgan Stanley Tejas Savant 29% 1-year accuracy 4 / 14 met price target	31% downside $28	Underweight Maintained	18 Nov 2024
Scotiabank Sung Ji Nam 60% 1-year accuracy 12 / 20 met price target	8% upside $44	Sector Outperform Maintained	8 Nov 2024
UBS Lu Li 100% 1-year accuracy 2 / 2 met price target	13% upside $46	Buy Maintained	7 Nov 2024
Needham Mike Matson 52% 1-year accuracy 64 / 122 met price target	8% upside $44	Buy Maintained	7 Nov 2024